Transforming the early detection
and intervention of cancer
Our Unique Biomarker
OncAlert Labs develops tests based on patented technology that detects specific protein markers known to indicate an elevated risk for early stage cancers, even prior to observation of visual or physical symptoms.
Actionable Insights for Earlier Oral Cancer
OraMark’s oral rinse collection method is easy to administer and non-invasive for the patient. The test delivers accurate, quantitative results that help optimize patient management and surveillance both pre- and post-biopsy.
Featured News and Events
June 21, 2017 |
Vigilant Biosciences Announces Further Clinical Data in Support of its OncAlert® Oral Cancer Product Line at IFOS ENT World Congress 2017 Symposium and at Annual MASCC Meeting
Company to exhibit as Bronze Sponsor of IFOS ENT World Congress and present interim analysis of European clinical studies in support of its OncAlert Oral Cancer product line
June 13, 2017 |
Vigilant Biosciences Announces Grant Award from National Institutes of Health
Grant to fund multi-institutional study on rapid, point-of-care test to aid in the early identification of oral and oropharyngeal cancer
May 10, 2017 |
Vigilant Biosciences Announces Commencement of FDA Studies for OncAlert® Cancer Test
Company begins drive toward FDA clearance of first and only test to detect a tumor-initiating stem cell-associated biomarker for oral and oropharyngeal cancer